Endothelin receptor antagonists
AssigneeConcert Pharmaceuticals, Inc.
InventorScott L. Harbeson
Life of this patent
Estimating the term…
Abstract
This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
Claims23
A compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- each Y is independently selected from hydrogen and deuterium, and Y2a is additionally selected from OH;
- each Z is independently selected from hydrogen, deuterium, and fluorine;
- and
- at least one Y or Z is deuterium.
(canceled)
A compound selected from:
- or a pharmaceutically acceptable salt thereof
19-24. (canceled)
26-31. (canceled)
A compound selected from any one of:
- each Y is independently selected from hydrogen or deuterium, and Y2a is additionally selected from OH;
- each Z is independently selected from hydrogen, deuterium, or fluorine;
- and at least one Y or Z is deuterium.
Dependencies are inferred from the claim text.